Elevar Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Elevar Therapeutics's estimated annual revenue is currently $21.9M per year.
- Elevar Therapeutics's estimated revenue per employee is $201,000
Employee Data
- Elevar Therapeutics has 109 Employees.
- Elevar Therapeutics grew their employee count by 45% last year.
Elevar Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP Sales U.S. | Reveal Email/Phone |
3 | Chief People Officer | Reveal Email/Phone |
4 | Marketing Director | Reveal Email/Phone |
5 | Sr Director, Controller | Reveal Email/Phone |
6 | Senior Director Global Alliance Management | Reveal Email/Phone |
7 | Director Quality Assurance | Reveal Email/Phone |
8 | Chief Medical Officer | Reveal Email/Phone |
9 | Executive Director, Commercial Operations | Reveal Email/Phone |
10 | Sr. Director | Reveal Email/Phone |
Elevar Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $9.2M | 46 | 5% | N/A | N/A |
#2 | $17.3M | 86 | 4% | N/A | N/A |
#3 | $20.5M | 102 | -1% | N/A | N/A |
#4 | $7.6M | 38 | -3% | N/A | N/A |
#5 | $14.9M | 74 | 37% | N/A | N/A |
#6 | $10.7M | 53 | -9% | N/A | N/A |
#7 | $6.2M | 31 | 7% | N/A | N/A |
#8 | $6.8M | 34 | 13% | N/A | N/A |
#9 | $5.4M | 27 | -36% | N/A | N/A |
#10 | $305.9M | 1522 | 8% | N/A | N/A |
What Is Elevar Therapeutics?
Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Our experience is rooted in oncology, and we apply the same rigor and diligence that comes with this knowledge to identifying and developing promising medicines for complex yet under-treated health conditions across a range of therapeutic areas. We develop and assess therapeutics based upon their ability to make a meaningful impact for patients and their treatment experiences. We invest in proven and promising therapeutics at various stages of development and advance them through clinical and regulatory processes with the goal of commercializing improved treatment options for patients and the healthcare providers who treat them. Elevating Outcomes: We take a relentless and inventive approach towards developing and advancing next generation, best-in-class therapies that have the potential to set new standards of care and improve treatment experiences. Evolving Therapeutic Potential: We identify areas where we can develop, build upon or evolve medicines that offer patients improved clinical outcomes. Engaging with Purpose: We are committed to engaging with the highest ethical standards, driven by a passion to address the underserved needs of patients, caregivers and healthcare providers. Elevar's corporate values are the essential tenets that define who we are and what we stand for. They guide us in our relationships with each other, in how we work and communicate, and ultimately how we will achieve our mission. Trust * Collaborative * Relentless * Brave * Accountable
keywords:N/AN/A
Total Funding
109
Number of Employees
$21.9M
Revenue (est)
45%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Elevar Therapeutics News
... Gradalis, Karyopharm Therapeutics, Sorrento Therapeutics, Novocure, Bayer, Elevar Therapeutics, EMD Merck, Gradalis, US Oncology.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.5M | 109 | 40% | N/A |
#2 | $31.6M | 109 | 51% | N/A |
#3 | $23.1M | 110 | 7% | N/A |
#4 | $29.7M | 110 | 6% | N/A |
#5 | $26M | 111 | 6% | N/A |